Moreover, More interestingly, the data from our on-going phase II clinical trial showed that BR-DIM treatment of PCa patients prior to radical prostatectomy led to the enhanced expression of let-7a, let-7b, let-7c, and let-7d in tumor specimens after BR-DIM intervention (Fig. 4A–C), and these results are consistent with decreased expression of EZH2 (Fig. 4D). Here, EZH2 is linked to neoplasm.